Predictors and consequences of adherence to the treatment of pediatric patients with attention-deficit/hyperactivity disorder in Central Europe and East Asia

Patient Preference and Adherence

Volumn 7, Issue , 2013, Pages 987-995

  Hong, Jihyung ^a   Novick, Diego ^a   Treuer, Tamás ^a   Montgomery, William ^b   Haynes, Virginia S ^a   Wu, Shenghu ^c   Haro, Josep Maria ^d  

^a ELI LILLY AND COMPANY   (United States)

^b ELI LILLY AUSTRALIA PTY LTD   (Australia)

^c Eli Lilly   (China)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

ADHD; Asia; Central Europe; Effectiveness; Non adherence; Response

Indexed keywords

METHYLPHENIDATE;

ARTICLE; ASIA; ATTENTION DEFICIT DISORDER; CENTRAL EUROPE; CHILD; CHILD HEALTH AND ILLNESS PROFILE CHILD EDITION; CHILD PARENT RELATION; CHILD SYMPTOM INVENTORY 4 CHECKLIST; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; EAST ASIA; EMOTIONAL STRESS; EUROPE; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; GOOD CLINICAL PRACTICE; HOMEOPATHY; HUMAN; HYPNOSIS; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OCCUPATIONAL THERAPY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PARENTAL ATTITUDE; PATIENT COMPLIANCE; PHYSIOTHERAPY; POST HOC ANALYSIS; PREDICTIVE VALUE; PSYCHOTHERAPY; QUALITY OF LIFE; RATING SCALE; SCHOOL CHILD; SPEECH THERAPY; TREATMENT REFUSAL; TREATMENT RESPONSE;

EID: 84885219308     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S50628     Document Type: Article

References (41)

1. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723.
2. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942-948.
3. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366(9481):237-248.
4. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry. 2010;10:67.
5. Barkley RA, Guevremont DC, Anastopoulos AD, DuPaul GJ, Shelton TL. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3-to 5-year follow-up survey. Pediatrics. 1993;92(2):212-218.
6. Mannuzza S, Klein RG, Bonagura N, Malloy P, Giampino TL, Addalli KA. Hyperactive boys almost grown up. V. Replication of psychiatric status. Arch Gen Psychiatry. 1991;48(1):77-83.
7. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry. 1998;155(4):493-498.
8. Hart EL, Lahey BB, Loeber R, Applegate B, Frick PJ. Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. J Abnorm Child Psychol. 1995;23(6): 729-749.
9. Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. J Am Acad Child Adolesc Psychiatry. 2000;39(11):1424-1431.
10. Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child. 2005;90 Suppl 1:i2-i7.
11. National Institute for Health and Clinical Excellence (NICE). Attention Deficit Hyperactivity Disorder. Diagnosis and Management of ADHD in Children, Young People and Adults. NICE Clinical Guideline 72. London: NICE; 2008.
12. Corkum P, Rimer P, Schachar R. Parental knowledge of attention-deficit hyperactivity disorder and opinions of treatment options: impact on enrollment and adherence to a 12-month treatment trial. Can J Psychiatry. 1999;44(10):1043-1048.
13. Michelson D, Faries D, Wernicke J, et al; Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83.
14. Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a random-ized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43(7):896-904.
15. Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. Postgrad Med. 2010;122(1):184-191.
16. Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry. 2004;43(5):559-567.
17. Marcus SC, Durkin M. Stimulant adherence and academic performance in urban youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50(5):480-489.
18. Gau SS, Shen HY, Chou MC, Tang CS, Chiu YN, Gau CS. Determinants of adherence to methylphenidate and the impact of poor adherence on maternal and family measures. J Child Adolesc Psychopharmacol. 2006;16(3):286-297.
19. Swanson J. Compliance with stimulants for attention-def icit/ hyperactivity disorder: issues and approaches for improvement. CNS Drugs. 2003;17(2):117-131.
20. Gau SS, Chen SJ, Chou WJ, et al. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Clin Psychiatry. 2008;69(1):131-140.
21. Barner JC, Khoza S, Oladapo A. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Curr Med Res Opin. 2011;27 Suppl 2:13-22.
22. Firestone P. Factors associated with children's adherence to stimulant medication. Am J Orthopsychiatry. 1982;52(3):447-457.
23. Sanchez RJ, Crismon ML, Barner JC, Bettinger T, Wilson JP. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy. 2005;25(7):909-917.
24. Thiruchelvam D, Charach A, Schachar RJ. Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2001;40(8):922-928.
25. Faraone SV, Biederman J, Zimmerman B. An analysis of patient adherence to treatment during a 1-year, open-label study of OROS methylphenidate in children with ADHD. J Atten Disord. 2007;11(2): 157-166.
26. Brown RT, Borden KA, Wynne ME, Spunt AL, Clingerman SR. Compliance with pharmacological and cognitive treatments for attention deficit disorder. J Am Acad Child Adolesc Psychiatry. 1987; 26(4):521-526.
27. Brown R, Borden K, Wynne M, Spunt A, Clingerman S. Patterns of compliance in a treatment program for attention deficit disorder. The Journal of Compliance in Health Care. 1988;3:23-29.
28. Brown RT, Borden KA, Clingerman SR. Adherence to methylphenidate therapy in a pediatric population: a preliminary investigation. Psychopharmacol Bull. 1985;21(1):28-36.
29. Weiss M, Jain U, Garland J. Clinical suggestions for management of stimulant treatment in adolescents. Can J Psychiatry. 2000;45(8): 717-723.
30. Martényi F, Treuer T, Gau SS, et al. Attention-deficit/hyperactivity disorder diagnosis, co-morbidities, treatment patterns, and quality of life in a pediatric population in central and eastern Europe and Asia. J Child Adolesc Psychopharmacol. 2009;19(4):363-376.
31. Martenyi F, Zavadenko NN, Jarkova NB, et al. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia. Eur Child Adolesc Psychiatry. 2010;19(1):57-66.
32. Martényi F, Zheng Y, Huang YS, et al. A prospective observational study of attention-deficit hyperactivity disorder in Asia: baseline characteristics of symptom severity and treatment options in a paediatric population. East Asian Arch Psychiatry. 2010;20(2):76-86.
33. Goetz M, Yeh CB, Ondrejka I, et al. A 12-month prospective, observational study of treatment regimen and quality of life associated with ADHD in central and eastern europe and eastern Asia. J Atten Disord. 2012;16(1):44-59.
34. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. 4th ed; text revision. Washington, DC: APA; 2000.
35. World Health Organization (WHO). The ICD-10 Classification of Mental and Behavioural Disorders. Clinical descriptions and diagnostic guidelines. Geneva: WHO; 1992.
36. Guy W. ECDEU Assessment Manual for Psychopharmacology (Revised). Bethesda, MD: US. Department of Health, Education and Welfare; 1976.
37. Gadow KD, Sprafkin J. Childhood Symptom Inventory 4. Screening and Norms Manual. Stony Brook, NY: Checkmate Plus; 2002.
38. Riley AW, Forrest CB, Starfield B, Rebok GW, Robertson JA, Green BF. The Parent Report Form of the CHIP-Child Edition: reliability and validity. Med Care. 2004;42(3):210-220.
39. Hinshaw SP, Scheffler RM, Fulton BD, et al. International variation in treatment procedures for ADHD: social context and recent trends. Psychiatr Serv. 2011;62(5):459-464.
40. Moon SY. Cultural perspectives on attention deficit hyperactivity disorder: a comparison between Korea and the US. Journal of International Business and Cultural Studies. 2011;6:1.
41. Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007;58(9):1187-1192